New agents for the treatment of acute myeloid leukemia

Keyphrases

• Acute Myeloid Leukemia 100%
• New Agents 100%
• Targeted Therapy 37%
• Chemotherapy 25%
• All-trans Retinoic Acid 12%
• Patient-centered 12%
• Gene mutation 12%
• Phase II Study 12%
• Therapeutic Strategies 12%
• Targeted Agents 12%
• Clinical Treatment 12%
• Multiple Pathways 12%
• Mammalian Target of Rapamycin (mTOR) 12%
• B-cell Lymphoma 2 (Bcl-2) 12%
• Prognostic Factors 12%
• Response Rate 12%
• Clinical Prognosis 12%
• Clinical Manifestations 12%
• Immunophenotyping 12%
• Reductase 12%
• Tyrosine Kinase Inhibitor 12%
• Farnesyltransferase Inhibitor 12%
• Complete Response 12%
• Diagnostic Study 12%
• Acute Promyelocytic Leukemia 12%
• Clofarabine 12%
• Cytogenetic Assay 12%
• Alkylating Agents 12%
• Molecular Abnormalities 12%
• Immunoconjugate 12%
• Purine Analogues 12%
• Multidrug Resistance Protein 12%
• Drug Inhibitors 12%
• Prognostic Genes 12%
• Molecular Genetic Testing 12%
• Ribonucleosides 12%
• Pathological Classification 12%
• CD33 Antibody 12%
• Protein Farnesyltransferase 12%

Medicine and Dentistry

• Acute Myeloid Leukemia 100%
• Targeted Therapy 37%
• Chemotherapy 25%
• Diseases 12%
• Acute Promyelocytic Leukemia 12%
• Clofarabine 12%
• Diagnosis 12%
• Mechanistic Target of Rapamycin 12%
• Gene Mutation 12%
• Prognostic Factor 12%
• Tretinoin 12%
• Tyrosine-Kinase Inhibitor 12%
• Alkylating Antineoplastic Agent 12%
• ABC Transporter Subfamily B 12%
• Purine 12%
• Laromustine 12%
• Farnesyltransferase Inhibitor 12%
• Immunophenotyping 12%
• Ribonucleoside 12%

Pharmacology, Toxicology and Pharmaceutical Science

• Acute Myeloid Leukemia 100%
• Chemotherapy 25%
• P-Glycoprotein 12%
• Protein Tyrosine Kinase Inhibitor 12%
• Retinoic Acid 12%
• Promyelocytic Leukemia 12%
• Alkylating Agent 12%
• Purine Derivative 12%
• Laromustine 12%
• Protein Farnesyltransferase Inhibitor 12%
• Disease 12%
• Mammalian Target of Rapamycin 12%
• Purine 12%
• Clofarabine 12%
• Ribonucleoside 12%